Design, Facile Synthesis, and Antibacterial Activity of Hybrid 1,3,4-thiadiazole-1,3,5-triazine Derivatives Tethered via -S- Bridge

Chemical Biology and Drug Design

Volumn 80, Issue 4, 2012, Pages 598-604

  Dubey, Vaibhav ^a   Pathak, Manish ^a   Bhat, Hans R ^a   Singh, Udaya P ^a  

^a SAM HIGGINBOTTOM UNIVERSITY OF AGRICULTURE   (India)

Author keywords

1,3,4 thiadiazole; 1,3,5 triazine; Antibacterial; Hybrid

Indexed keywords

2N,4N BIS(4 BROMOPHENYL) 6 ((5 ((3,5 DIMETHYL 1 PHENYL 4,5 DIHYDRO 1H PYRAZOL 4 YL)AMINO) 1,3,4 THIADIAZOL 2 YL)THIO) 1,3,5 TRIAZINE 2,4 DIAMINE; 2N,4N BIS(4 CHLOROPHENYL) 6 [(5 (3,5 DIMETHYL 1 PHENYL 4,5 DIHYDRO 1H PYRAZOL 4 YL)AMINO) 1,3,4 THIADIAZOL-2-YL)THIO] 1,3,5 TRIAZINE 2,4 DIAMINE; 6 ((5 ((3,5 DIMETHYL 1 PHENYL 4,5 DIHYDRO 1H PYRAZOL 4 YL)AMINO) 1,3,4 THIADIAZOL 2 YL)THIO) 2N, 4N BIS(4 FLUOROPHENYL) 1,3,5 TRIAZINE 2,4 DIAMINE; 6 ((5 ((3,5 DIMETHYL 1 PHENYL 4,5 DIHYDRO 1H PYRAZOL 4 YL)AMINO) 1,3,4 THIADIAZOL 2 YL)THIO) 2N, 4N DI P TOLYL 1,3,5 TRIAZINE 2,4 DIAMINE; 6 ((5 ((3,5 DIMETHYL 1 PHENYL 4,5 DIHYDRO 1H PYRAZOL 4 YL)AMINO) 1,3,4 THIADIAZOL 2 YL)THIO) 2N,4N BIS(4 METHOXYPHENYL) 1,3,5 TRIAZINE 2,4 DIAMINE; 6 ((5 ((3,5 DIMETHYL 1 PHENYL 4,5 DIHYDRO 1H PYRAZOL 4 YL)AMINO) 1,3,4 THIADIAZOL 2 YL)THIO) 2N,4N BIS(4 NITROPHENYL) 1,3,5 TRIAZINE 2,4 DIAMINE; ANTIINFECTIVE AGENT; CEFIXIME; TRIAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG SYNTHESIS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; NONHUMAN; PRIORITY JOURNAL; SPECTROSCOPY;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; HUMANS; THIADIAZOLES; TRIAZINES;

NEGIBACTERIA; POSIBACTERIA;

EID: 84866634004     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2012.01433.x     Document Type: Article

References (19)

1. Tan Y.T., Tillett D.J., McKay I.A. (2000) Molecular strategies for overcoming antibiotic resistance in bacteria. Mol Med Today;6:309-314.
2. Klevens R.M., Morrison M.A., Nadle J., Petit S., Gershman K., Ray S., Harrison L.H. et al. (2007) Active Bacterial Core surveillance (ABCs) MRSA Investigators. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA;298:1763-1771.
3. Courvalin P. (2006) Vancomycin resistance in gram-positive cocci. Clin Infect Dis;42(Suppl 1):S25-S34.
4. Go E.S., Urban C., Burns J., Kreiswirth B., Eisner W., Mariann N., Mosinka-Snipas K., Rahal J.J. (1994) Clinical and molecular epidemiology of acinetobacter infections sensitive only to polymyxin B and sulbactam. Lancet;344:1329-1332.
5. Afzal M.S., Livermore D.M. (1998) Worldwide emergence of carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother;41:576-577.
6. Appelbaum P.C. (2007) Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents;30:398-408.
7. Kumarasamy K.K., Toleman M.A., Walsh T.R., Bagaria J., Butt F., Balakrishnan R., Chaudhary U. et al. (2010) Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis;10:597-602.
8. Rybak M.J., McGrath B.J. (1996) Combination antimicrobial therapy for bacterial infections. Guidelines for the clinician. Drugs;52:390-405.
9. Meunier B. (2008) Hybrid molecules with a dual mode of action: dream or reality? Acc Chem Res;41:69-77.
10. Singh U.P., Singh R.K., Bhat H.R., Subhashchandra Y.P., Kumar V., Kumawat M.K., Gahtori P. (2011) Synthesis and antibacterial evaluation of series of novel tri-substituted-s-triazine derivatives. Med Chem Res;20:1603-1610.
11. Bhat H.R., Singh U.P., Subhashchandra Y.P., Kumar V., Gahtori P., Das A., Chetia D., Prakash A., Mahanta J. (2011) Synthesis and antimalarial activity evaluation of some analogues of 7-chloro-N-[3-(4, 6-diamino-1, 3, 5-triazin-2-ylamino)propyl]quinoline-4-amine derivatives. Arabian J Chem;in press: doi: 10.1016/j.arabjc.2011.07.001.
12. Kumawat M.K., Singh U.P., Singh B., Prakash A., Chetia D. (2011) Synthesis and antimalarial activity evaluation of 3-(3-(7-chloroquinolin-4-ylamino) propyl)-1, 3-thiazinan-4-one derivatives. Arabian J Chem;in press: doi: 10.1016/j.arabjc.2011.07.007.
13. Singh U.P., Bhat H.R., Gahtori P. (2012) Antifungal activity, SAR and physicochemical correlation of some hybrid thiazole-1, 3, 5-triazine derivatives. J Mycol Med;22:134-141.
14. Gahtori P., Ghosh S.K., Singh B., Singh U.P., Bhat H.R., Archana U. (2012) Synthesis, SAR and antibacterial activity of hybrid chloro, dichloro-phenylthiazolyl-s-triazines. Saudi Pharm J;20:35-43.
15. Gahtori P., Ghosh S.K., Pratap P., Prakash A., Gogoi K., Singh U.P. (2012) Antimalarial evaluation and docking studies on hybrid phenylthiazolyl-1, 3, 5-triazine derivatives: a novel and potential antifolate lead for Pf-DHFR-TS inhibition. Exp Parasitol;130:292-299.
16. Bhat H.R., Ghosh S.K., Prakash A., Gogoi K., Singh U.P. (2012) In vitro antimalarial activity and molecular docking analysis of 4-aminoquinoline clubbed 1, 3, 5-triazine derivatives. Lett Appl Microbiol;54:483-486.
17. Guha P.C. (1922) Constitution of the so-called dithio-urazole of martin freund. II. New methods of synthesis, isomerism and poly-derivatives. J Am Chem Soc;44:1510-1517.
18. National Committee for Clinical Laboratory Standards. (1982) Standard Methods for Dilution Antimicrobial Susceptibility Test for Bacteria Which Grow Aerobically. Villanova: NCCLS; p. 242.
19. Lalitha M.K. (2004) Manual on Antimicrobial Susceptibility Testing (Under the Auspices of Indian Association of Medical Microbiologists). Vellore, India: C.M.C. Vellore.